Ewha Med J.  2017 Jan;40(1):17-21. 10.12771/emj.2017.40.1.17.

Anticancer Effect of Selenium

• Woo J
• Lim W

• KMID: 2367892
• DOI: http://doi.org/10.12771/emj.2017.40.1.17

Abstract

Selenium is an essential microelement in animals including human. Selenium plays an important role in cellular functions such as deoxygenation and detoxification. Also, it can be used in treatment of cardiac disease, hepatic disease, AIDS and various cancers. Recent meta-analysis showed that high selenium exposure was associated with decreased risk of several cancers. Selenium has an effect on anticarcinogesis through several mechanisms, which are regulation of cell cycles, apoptosis, DNA damage and repair, inhibition of cellular adhesion and migration, anti-angiogenesis and immune modulation. Even though many laboratory studies have provided convincing evidence of these mechanisms, results from epidemiologic and clinical studies of selenium does not coincide with each other. Well-designed trials considering dosage and chemical form of selenium supplement as well as confounding factors and long-term follow-up of them would be needed to use selenium in chemoprevention and therapy of cancers.

Keyword

Selenium; Chemoprevention; Neoplasms

MeSH Terms

Animals
Apoptosis
Cell Cycle
Chemoprevention
DNA Damage
Follow-Up Studies
Heart Diseases
Humans
Selenium*
Selenium

Reference

1. Merian E. Introduction on environmental chemistry and global cycles of chromium, nickel, cobalt beryllium, arsenic, cadmium and selenium, and their derivatives. Toxicol Environ Chem. 1984; 8:9–38.

2. Allan CB, Lacourciere GM, Stadtman TC. Responsiveness of selenoproteins to dietary selenium. Annu Rev Nutr. 1999; 19:1–16.

3. Behne D, Kyriakopoulos A. Mammalian selenium-containing proteins. Annu Rev Nutr. 2001; 21:453–473.

4. Neve J. Selenium as a risk factor for cardiovascular diseases. J Cardiovasc Risk. 1996; 3:42–47.

5. Kohrle J. The deiodinase family: selenoenzymes regulating thyroid hormone availability and action. Cell Mol Life Sci. 2000; 57:1853–1863.

6. Ip C, Ganther H. Biological activities of trimethylselenonium as influenced by arsenite. J Inorg Biochem. 1992; 46:215–222.

7. Rayman MP. The importance of selenium to human health. Lancet. 2000; 356:233–241.

8. Shamberger RJ, Frost DV. Possible protective effect of selenium against human cancer. Can Med Assoc J. 1969; 100:682.

9. Schrauzer GN, Rhead WJ. Interpretation of the methylene blue reduction test of human plasma and the possible cancer protecting effect of selenium. Experientia. 1971; 27:1069–1071.

10. Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Chalker DK, Chow J, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA. 1996; 276:1957–1963.

11. Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011; 306:1549–1556.

12. Kristal AR, Darke AK, Morris JS, Tangen CM, Goodman PJ, Thompson IM, et al. Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk. J Natl Cancer Inst. 2014; 106:djt456.

13. Cai X, Wang C, Yu W, Fan W, Wang S, Shen N, et al. Selenium exposure and cancer risk: an updated meta-analysis and meta-regression. Sci Rep. 2016; 6:19213.

14. Lobinski R, Edmonds JS, Suzuki KT, Uden PC. Species-selective determination of selenium compounds in biological materials. Pure Appl Chem. 2000; 72:447–461.

15. Combs GF Jr. Current evidence and research needs to support a health claim for selenium and cancer prevention. J Nutr. 2005; 135:343–347.

16. Whanger PD. Selenium and its relationship to cancer: an update. Br J Nutr. 2004; 91:11–28.

17. Monsen ER. Dietary reference intakes for the antioxidant nutrients: vitamin C, vitamin E, selenium, and carotenoids. J Am Diet Assoc. 2000; 100:637–640.

18. Yang G, Zhou R. Further observations on the human maximum safe dietary selenium intake in a seleniferous area of China. J Trace Elem Electrolytes Health Dis. 1994; 8:159–165.

19. Yang G, Yin S, Zhou R, Gu L, Yan B, Liu Y, et al. Studies of safe maximal daily dietary Se-intake in a seleniferous area in China. Part II: relation between Se-intake and the manifestation of clinical signs and certain biochemical alterations in blood and urine. J Trace Elem Electrolytes Health Dis. 1989; 3:123–130.

20. Veres Z, Kim IY, Scholz TD, Stadtman TC. Selenophosphate synthetase. Enzyme properties and catalytic reaction. J Biol Chem. 1994; 269:10597–10603.

21. El-Bayoumy K, Sinha R. Mechanisms of mammary cancer chemoprevention by organoselenium compounds. Mutat Res. 2004; 551:181–197.

22. Abdulah R, Miyazaki K, Nakazawa M, Koyama H. Chemical forms of selenium for cancer prevention. J Trace Elem Med Biol. 2005; 19:141–150.

23. Ip C. Lessons from basic research in selenium and cancer prevention. J Nutr. 1998; 128:1845–1854.

24. Ghose A, Fleming J, Harrison PR. Selenium and signal transduction: roads to cell death and anti-tumour activity. Biofactors. 2001; 14:127–133.

25. Gromadzinska J, Reszka E, Bruzelius K, Wasowicz W, Akesson B. Selenium and cancer: biomarkers of selenium status and molecular action of selenium supplements. Eur J Nutr. 2008; 47:Suppl 2. 29–50.

26. Blot WJ, Li JY, Taylor PR, Guo W, Dawsey S, Wang GQ, et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst. 1993; 85:1483–1492.

27. Yu SY, Zhu YJ, Li WG. Protective role of selenium against hepatitis B virus and primary liver cancer in Qidong. Biol Trace Elem Res. 1997; 56:117–124.

28. Blot WJ, Li JY, Taylor PR, Guo W, Dawsey SM, Li B. The Linxian trials: mortality rates by vitamin-mineral intervention group. Am J Clin Nutr. 1995; 62:6 Suppl. 1424S–1426S.

29. Bonelli L, Camoriano A, Ravelli P, Missale G, Bruzzi P, Aste H. Reduction of the incidence of metachronous adenomas of the large bowel by means of antioxidants. In : Proceedings of International Selenium Tellurium Development Association; 1998; Scottsdale, AZ. p. 91–94.

30. Prasad MP, Mukundan MA, Krishnaswamy K. Micronuclei and carcinogen DNA adducts as intermediate end points in nutrient intervention trial of precancerous lesions in the oral cavity. Eur J Cancer B Oral Oncol. 1995; 31B:155–159.

31. McKeehan WL, Hamilton WG, Ham RG. Selenium is an essential trace nutrient for growth of WI-38 diploid human fibroblasts. Proc Natl Acad Sci U S A. 1976; 73:2023–2027.

32. Pines J. The cell cycle kinases. Semin Cancer Biol. 1994; 5:305–313.

33. Zeng H. Selenite and selenomethionine promote HL-60 cell cycle progression. J Nutr. 2002; 132:674–679.

34. Saito Y, Yoshida Y, Akazawa T, Takahashi K, Niki E. Cell death caused by selenium deficiency and protective effect of antioxidants. J Biol Chem. 2003; 278:39428–39434.

35. Irmak MB, Ince G, Ozturk M, Cetin-Atalay R. Acquired tolerance of hepatocellular carcinoma cells to selenium deficiency: a selective survival mechanism? Cancer Res. 2003; 63:6707–6715.

36. Jiang C, Wang Z, Ganther H, Lu J. Distinct effects of methylseleninic acid versus selenite on apoptosis, cell cycle, and protein kinase pathways in DU145 human prostate cancer cells. Mol Cancer Ther. 2002; 1:1059–1066.

37. Hu H, Li GX, Wang L, Watts J, Combs GF Jr, Lu J. Methylseleninic acid enhances taxane drug efficacy against human prostate cancer and down-regulates antiapoptotic proteins Bcl-XL and survivin. Clin Cancer Res. 2008; 14:1150–1158.

38. Kaeck M, Lu J, Strange R, Ip C, Ganther HE, Thompson HJ. Differential induction of growth arrest inducible genes by selenium compounds. Biochem Pharmacol. 1997; 53:921–926.

39. Sinha R, Medina D. Inhibition of cdk2 kinase activity by methylselenocysteine in synchronized mouse mammary epithelial tumor cells. Carcinogenesis. 1997; 18:1541–1547.

40. Pagmantidis V, Meplan C, van Schothorst EM, Keijer J, Hesketh JE. Supplementation of healthy volunteers with nutritionally relevant amounts of selenium increases the expression of lymphocyte protein biosynthesis genes. Am J Clin Nutr. 2008; 87:181–189.

41. Selenius M, Fernandes AP, Brodin O, Bjornstedt M, Rundlof AK. Treatment of lung cancer cells with cytotoxic levels of sodium selenite: effects on the thioredoxin system. Biochem Pharmacol. 2008; 75:2092–2099.

42. Rudolf E, Rudolf K, Cervinka M. Selenium activates p53 and p38 pathways and induces caspase-independent cell death in cervical cancer cells. Cell Biol Toxicol. 2008; 24:123–141.

43. Thirunavukkarasu C, Premkumar K, Sheriff AK, Sakthisekaran D. Sodium selenite enhances glutathione peroxidase activity and DNA strand breaks in hepatoma induced by N-nitrosodiethylamine and promoted by phenobarbital. Mol Cell Biochem. 2008; 310:129–139.

44. Letavayova L, Vlasakova D, Spallholz JE, Brozmanova J, Chovanec M. Toxicity and mutagenicity of selenium compounds in Saccharomyces cerevisiae. Mutat Res. 2008; 638:1–10.

45. Smith ML, Lancia JK, Mercer TI, Ip C. Selenium compounds regulate p53 by common and distinctive mechanisms. Anticancer Res. 2004; 24:1401–1408.

46. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature. 1980; 284:67–68.

47. Iwamoto Y, Robey FA, Graf J, Sasaki M, Kleinman HK, Yamada Y, et al. YIGSR, a synthetic laminin pentapeptide, inhibits experimental metastasis formation. Science. 1987; 238:1132–1134.

48. Yan L, Frenkel GD. Inhibition of cell attachment by selenite. Cancer Res. 1992; 52:5803–5807.

49. Yan L, Frenkel GD. Effect of selenite on cell surface fibronectin receptor. Biol Trace Elem Res. 1994; 46:79–89.

50. Yoon SO, Kim MM, Chung AS. Inhibitory effect of selenite on invasion of HT1080 tumor cells. J Biol Chem. 2001; 276:20085–20092.

51. Forget MA, Desrosiers RR, Beliveau R. Physiological roles of matrix metalloproteinases: implications for tumor growth and metastasis. Can J Physiol Pharmacol. 1999; 77:465–480.

52. Kim Y, Lee YS, Choe J, Lee H, Kim YM, Jeoung D. CD44-epidermal growth factor receptor interaction mediates hyaluronic acid-promoted cell motility by activating protein kinase C signaling involving Akt, Rac1, Phox, reactive oxygen species, focal adhesion kinase, and MMP-2. J Biol Chem. 2008; 283:22513–22528.

53. Unni E, Kittrell FS, Singh U, Sinha R. Osteopontin is a potential target gene in mouse mammary cancer chemoprevention by Se-methylselenocysteine. Breast Cancer Res. 2004; 6:R586–R592.

54. Wang Z, Hu H, Li G, Lee HJ, Jiang C, Kim SH, et al. Methylseleninic acid inhibits microvascular endothelial G1 cell cycle progression and decreases tumor microvessel density. Int J Cancer. 2008; 122:15–24.

55. Bhattacharya A, Seshadri M, Oven SD, Toth K, Vaughan MM, Rustum YM. Tumor vascular maturation and improved drug delivery induced by methylselenocysteine leads to therapeutic synergy with anticancer drugs. Clin Cancer Res. 2008; 14:3926–3932.

56. Jiang C, Ganther H, Lu J. Monomethyl selenium: specific inhibition of MMP-2 and VEGF expression: implications for angiogenic switch regulation. Mol Carcinog. 2000; 29:236–250.

57. Kiremidjian-Schumacher L, Roy M, Wishe HI, Cohen MW, Stotzky G. Supplementation with selenium augments the functions of natural killer and lymphokine-activated killer cells. Biol Trace Elem Res. 1996; 52:227–239.

58. Arthur JR, McKenzie RC, Beckett GJ. Selenium in the immune system. J Nutr. 2003; 133:5 Suppl 1. 1457S–1459S.

59. Ferencík M, Ebringer L. Modulatory effects of selenium and zinc on the immune system. Folia Microbiol (Praha). 2003; 48:417–426.